PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
-12.50%
Both companies reducing costs. Martin Whitman would check industry efficiency trends.
12.50%
Gross profit growth below 50% of CRVO's 804.26%. Michael Burry would check for structural issues.
No Data
No Data available this quarter, please select a different quarter.
37.48%
R&D growth 1.1-1.25x CRVO's 34.05%. Bill Ackman would demand evidence of superior returns.
21.30%
G&A growth 1.1-1.25x CRVO's 18.03%. Bill Ackman would demand evidence of necessary spending.
100.00%
Marketing expense change of 100.00% while CRVO maintains spending. Bruce Berkowitz would investigate effectiveness.
No Data
No Data available this quarter, please select a different quarter.
32.37%
Operating expenses growth 1.1-1.25x CRVO's 27.15%. Bill Ackman would demand justification.
29.39%
Similar total costs growth to CRVO's 27.15%. Walter Schloss would investigate norms.
No Data
No Data available this quarter, please select a different quarter.
-12.50%
D&A reduction while CRVO shows 100.00% growth. Joel Greenblatt would examine efficiency.
-30.36%
Both companies show EBITDA decline. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-29.39%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
14.89%
Other expenses growth less than half of CRVO's 741.40%. David Dodd would verify if advantage is sustainable.
-30.95%
Pre-tax income decline while CRVO shows 7.85% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Both companies reducing tax expense. Martin Whitman would check patterns.
-30.95%
Net income decline while CRVO shows 7.85% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-22.58%
EPS decline while CRVO shows 34.15% growth. Joel Greenblatt would examine position.
-22.58%
Diluted EPS decline while CRVO shows 34.15% growth. Joel Greenblatt would examine position.
7.95%
Share count reduction exceeding 1.5x CRVO's 41.04%. David Dodd would verify capital allocation.
7.95%
Diluted share reduction exceeding 1.5x CRVO's 41.04%. David Dodd would verify capital allocation.